Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Collagen Solutions PLC to work with renowned burns unit

The med-tech group is developing a range of collagen-based medical implants
Collagen Solutions PLC to work with renowned burns unit
The two organisations will research a better way to treat burn injuries

--ADDS SHARE PRICE AND BROKER COMMENT---

Collagen Solutions PLC (LON:COS) has established a research collaboration with the Blond McIndoe Research Foundation (BMRF), a not-for-profit burns treatment specialist based at the Queen Victoria Hospital, East Grinstead.

The med-tech group is developing a range of collagen-based medical implants and the two will investigate how to use Collagen’s products to find treatments that reduce the side effects of skin grafts.

Collagen added it sees the combination of BMRF's experience in culturing cells specifically for treatment of burns and the use of high quality medical grade collagen as a potentially effective treatment.

Dr Stewart White, Collagen Solutions’ chief executive, said the care and treatment of burns represented a significant clinical need.

BMRF's experience in the treatment of burns and wound care using the patient's own cells is truly world-leading, he said.

Initially, the project will determine that collagen formulations can provide a successful scaffold for these living cells, he added, after which the two organisations will work on a delivery method.

Broker Panmure said: "Today’s news further demonstrates, in our view, the breadth of opportunity for Collagen Solutions’ technologies. We retain our investment thesis unchanged."

The broker has a 'buy' stance and a target price of 10p.

Shares added  4% to stand at 6.50p on the day.

PhilW.jpg
Why Invest In Collagen Solutions PLC? Read More Here

Register here to be notified of future COS Company articles
View full COS profile

Collagen Solutions PLC Timeline

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
Pollen2.jpg
January 19 2017
Turnover was £40.4mln in the six months to December
Antibiotic
January 19 2017
It completed its long-mooted listing on Nasdaq where, some would argue, pharmaceutical companies (and how to value them) are better understood.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use